PYC vs. DEST, ROQ, RENE, VAL, SALV, BSFA, NFX, OVB, ONC, and OCTP
Should you be buying Physiomics stock or one of its competitors? The main competitors of Physiomics include Destiny Pharma (DEST), Roquefort Therapeutics (ROQ), ReNeuron Group (RENE), ValiRx (VAL), SalvaRx Group (SALV), BSF Enterprise (BSFA), Nuformix (NFX), Ovoca Bio (OVB), Oncimmune (ONC), and Oxford Cannabinoid Technologies (OCTP). These companies are all part of the "biotechnology" industry.
Physiomics vs.
Physiomics (LON:PYC) and Destiny Pharma (LON:DEST) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.
Physiomics received 5 more outperform votes than Destiny Pharma when rated by MarketBeat users. However, 59.52% of users gave Destiny Pharma an outperform vote while only 55.56% of users gave Physiomics an outperform vote.
Physiomics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Destiny Pharma has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.
Physiomics has higher revenue and earnings than Destiny Pharma. Physiomics is trading at a lower price-to-earnings ratio than Destiny Pharma, indicating that it is currently the more affordable of the two stocks.
21.9% of Destiny Pharma shares are owned by institutional investors. 4.2% of Physiomics shares are owned by insiders. Comparatively, 25.9% of Destiny Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Destiny Pharma had 1 more articles in the media than Physiomics. MarketBeat recorded 1 mentions for Destiny Pharma and 0 mentions for Physiomics. Destiny Pharma's average media sentiment score of 0.54 beat Physiomics' score of 0.00 indicating that Destiny Pharma is being referred to more favorably in the news media.
Destiny Pharma has a net margin of 0.00% compared to Physiomics' net margin of -106.80%. Destiny Pharma's return on equity of -67.29% beat Physiomics' return on equity.
Summary
Destiny Pharma beats Physiomics on 9 of the 14 factors compared between the two stocks.
Get Physiomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Physiomics Competitors List
Related Companies and Tools
This page (LON:PYC) was last updated on 4/24/2025 by MarketBeat.com Staff
Buy PYC Stock Free PYC Stock Alerts